Sertraline and desmethylsertraline in human breast milk and nursing infants

Zachary N. Stowe, Michael J. Owens, Jacque C. Landry, Clinton D. Kilts, Timothy Ely, Alexis Llewellyn, Charles Nemeroff

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Objective: The purpose of this study was to determine the concentrations of sertraline and desmethylsertraline in both human breast milk and infant serum. Method: Breast milk samples from 12 women were collected at specific time intervals after oral doses of sertraline (25-200 mg once daily). For 11 mother-infant pairs, maternal serum levels 24 hours after a dose and their infants'serum levels 2-4 hours after nursing were ascertained by high- performance liquid chromatography. Results; Sertraline and desmethylsertraline were present in all breast milk samples, with a gradient from 'fore' milk to 'hind' milk. The highest concentrations of sertraline were observed in bind milk 7-10 hours after maternal dose. Increasing the maternal dose of sertraline resulted in increased breast milk concentrations of both sertraline and desmethylsertraline. Detectable concentrations of sertraline were found in three nursing infants and desmethylsertraline in six. No adverse effects of exposure were observed in any infant. Conclusions: Sertraline and desmethylsertraline were present in the breast milk of nursing women treated with sertraline. Concentrations were affected by aliquot of milk sampled, time after maternal dose, and maternal daily dose. The infants' serum concentrations detected were below the detection limit of most commercial laboratories. The presence of desmethylsertraline in six infants' samples underscores the importance of metabolite monitoring in determining infant exposure. Estimates of daily infant exposure can be determined after analysis of sertraline and desmethylsertraline concentrations from one full breast at maternal serum steady state. Future studies of breast milk and infant serum samples should address these issues.

Original languageEnglish
Pages (from-to)1255-1260
Number of pages6
JournalAmerican Journal of Psychiatry
Volume154
Issue number9
StatePublished - Sep 1 1997
Externally publishedYes

Fingerprint

Sertraline
Human Milk
Nursing
Mothers
Milk
Serum
desmethylsertraline
Limit of Detection
Breast
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Stowe, Z. N., Owens, M. J., Landry, J. C., Kilts, C. D., Ely, T., Llewellyn, A., & Nemeroff, C. (1997). Sertraline and desmethylsertraline in human breast milk and nursing infants. American Journal of Psychiatry, 154(9), 1255-1260.

Sertraline and desmethylsertraline in human breast milk and nursing infants. / Stowe, Zachary N.; Owens, Michael J.; Landry, Jacque C.; Kilts, Clinton D.; Ely, Timothy; Llewellyn, Alexis; Nemeroff, Charles.

In: American Journal of Psychiatry, Vol. 154, No. 9, 01.09.1997, p. 1255-1260.

Research output: Contribution to journalArticle

Stowe, ZN, Owens, MJ, Landry, JC, Kilts, CD, Ely, T, Llewellyn, A & Nemeroff, C 1997, 'Sertraline and desmethylsertraline in human breast milk and nursing infants', American Journal of Psychiatry, vol. 154, no. 9, pp. 1255-1260.
Stowe ZN, Owens MJ, Landry JC, Kilts CD, Ely T, Llewellyn A et al. Sertraline and desmethylsertraline in human breast milk and nursing infants. American Journal of Psychiatry. 1997 Sep 1;154(9):1255-1260.
Stowe, Zachary N. ; Owens, Michael J. ; Landry, Jacque C. ; Kilts, Clinton D. ; Ely, Timothy ; Llewellyn, Alexis ; Nemeroff, Charles. / Sertraline and desmethylsertraline in human breast milk and nursing infants. In: American Journal of Psychiatry. 1997 ; Vol. 154, No. 9. pp. 1255-1260.
@article{7b79bbce758b445089904543d66e9100,
title = "Sertraline and desmethylsertraline in human breast milk and nursing infants",
abstract = "Objective: The purpose of this study was to determine the concentrations of sertraline and desmethylsertraline in both human breast milk and infant serum. Method: Breast milk samples from 12 women were collected at specific time intervals after oral doses of sertraline (25-200 mg once daily). For 11 mother-infant pairs, maternal serum levels 24 hours after a dose and their infants'serum levels 2-4 hours after nursing were ascertained by high- performance liquid chromatography. Results; Sertraline and desmethylsertraline were present in all breast milk samples, with a gradient from 'fore' milk to 'hind' milk. The highest concentrations of sertraline were observed in bind milk 7-10 hours after maternal dose. Increasing the maternal dose of sertraline resulted in increased breast milk concentrations of both sertraline and desmethylsertraline. Detectable concentrations of sertraline were found in three nursing infants and desmethylsertraline in six. No adverse effects of exposure were observed in any infant. Conclusions: Sertraline and desmethylsertraline were present in the breast milk of nursing women treated with sertraline. Concentrations were affected by aliquot of milk sampled, time after maternal dose, and maternal daily dose. The infants' serum concentrations detected were below the detection limit of most commercial laboratories. The presence of desmethylsertraline in six infants' samples underscores the importance of metabolite monitoring in determining infant exposure. Estimates of daily infant exposure can be determined after analysis of sertraline and desmethylsertraline concentrations from one full breast at maternal serum steady state. Future studies of breast milk and infant serum samples should address these issues.",
author = "Stowe, {Zachary N.} and Owens, {Michael J.} and Landry, {Jacque C.} and Kilts, {Clinton D.} and Timothy Ely and Alexis Llewellyn and Charles Nemeroff",
year = "1997",
month = "9",
day = "1",
language = "English",
volume = "154",
pages = "1255--1260",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "9",

}

TY - JOUR

T1 - Sertraline and desmethylsertraline in human breast milk and nursing infants

AU - Stowe, Zachary N.

AU - Owens, Michael J.

AU - Landry, Jacque C.

AU - Kilts, Clinton D.

AU - Ely, Timothy

AU - Llewellyn, Alexis

AU - Nemeroff, Charles

PY - 1997/9/1

Y1 - 1997/9/1

N2 - Objective: The purpose of this study was to determine the concentrations of sertraline and desmethylsertraline in both human breast milk and infant serum. Method: Breast milk samples from 12 women were collected at specific time intervals after oral doses of sertraline (25-200 mg once daily). For 11 mother-infant pairs, maternal serum levels 24 hours after a dose and their infants'serum levels 2-4 hours after nursing were ascertained by high- performance liquid chromatography. Results; Sertraline and desmethylsertraline were present in all breast milk samples, with a gradient from 'fore' milk to 'hind' milk. The highest concentrations of sertraline were observed in bind milk 7-10 hours after maternal dose. Increasing the maternal dose of sertraline resulted in increased breast milk concentrations of both sertraline and desmethylsertraline. Detectable concentrations of sertraline were found in three nursing infants and desmethylsertraline in six. No adverse effects of exposure were observed in any infant. Conclusions: Sertraline and desmethylsertraline were present in the breast milk of nursing women treated with sertraline. Concentrations were affected by aliquot of milk sampled, time after maternal dose, and maternal daily dose. The infants' serum concentrations detected were below the detection limit of most commercial laboratories. The presence of desmethylsertraline in six infants' samples underscores the importance of metabolite monitoring in determining infant exposure. Estimates of daily infant exposure can be determined after analysis of sertraline and desmethylsertraline concentrations from one full breast at maternal serum steady state. Future studies of breast milk and infant serum samples should address these issues.

AB - Objective: The purpose of this study was to determine the concentrations of sertraline and desmethylsertraline in both human breast milk and infant serum. Method: Breast milk samples from 12 women were collected at specific time intervals after oral doses of sertraline (25-200 mg once daily). For 11 mother-infant pairs, maternal serum levels 24 hours after a dose and their infants'serum levels 2-4 hours after nursing were ascertained by high- performance liquid chromatography. Results; Sertraline and desmethylsertraline were present in all breast milk samples, with a gradient from 'fore' milk to 'hind' milk. The highest concentrations of sertraline were observed in bind milk 7-10 hours after maternal dose. Increasing the maternal dose of sertraline resulted in increased breast milk concentrations of both sertraline and desmethylsertraline. Detectable concentrations of sertraline were found in three nursing infants and desmethylsertraline in six. No adverse effects of exposure were observed in any infant. Conclusions: Sertraline and desmethylsertraline were present in the breast milk of nursing women treated with sertraline. Concentrations were affected by aliquot of milk sampled, time after maternal dose, and maternal daily dose. The infants' serum concentrations detected were below the detection limit of most commercial laboratories. The presence of desmethylsertraline in six infants' samples underscores the importance of metabolite monitoring in determining infant exposure. Estimates of daily infant exposure can be determined after analysis of sertraline and desmethylsertraline concentrations from one full breast at maternal serum steady state. Future studies of breast milk and infant serum samples should address these issues.

UR - http://www.scopus.com/inward/record.url?scp=0030799747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030799747&partnerID=8YFLogxK

M3 - Article

C2 - 9286185

AN - SCOPUS:0030799747

VL - 154

SP - 1255

EP - 1260

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 9

ER -